Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listXL518

XL518

XL518 Structural

What is XL518?

Absorption

Following oral dosing of 60 mg once daily in cancer patients, the median time to achieve peak plasma levels (Tmax) was 2.4 (range:1–24) hours, geometric mean steady-state AUC0-24h was 4340 ng?h/mL (61% CV) and Cmax was 273 ng/mL (60% CV). The absolute bioavailability of COTELLIC was 46% (90% CI: 40%, 53%) in healthy subjects. A high‐fat meal (comprised of approximately 150 calories from protein, 250 calories from carbohydrate, and 500–600 calories from fat) had no effect on cobimetinib AUC and Cmax after a single 20 mg COTELLIC was administered to healthy subjects.

Toxicity

The most common adverse effects (>20%) for cobimetinib are diarrhea, photosensitivity reactions, nausea, fever and vomiting.

Description

Cobimetinib, codeveloped by Genentech and Exelixis, was approved in August 2015 in Switzerland and November 2015 in the U.S. and Europe for the treatment of unresectable or metastatic BRAFV600 mutationpositive melanoma when used in combination with vemurafenib. Cobimetinib is a potent, highly selective reversible inhibitor of mitogen-activated protein kinases (MEK) 1 and 2,120 which serves to inhibit phosphorylation of ERK1/2,121 disrupting the MAPK pathway which is responsible for cell proliferation, cell survival, and migration.122 Combination of cobimetinib with vemurafenib, an important BRAF inhibitor,123 enables targeting of multiple points on the MAPK pathway, leading to overall enhanced tumor cell apoptosis and response as compared to stand-alone treatment with vemurafenib.124 Specifically, in a representative trial of previously untreated patients with BRAFV600 mutation-positive, unresectable, stage IIIc or IV melanoma, combination of these two therapies led to a significantly improved progression-free survival and overall response rate versus patients treated only with vemurafenib.

The Uses of XL518

A potent, selective, orally bioavailable inhibitor of MEK1, a component of the RAS/RAF/MEK/ERK pathway. It inhibits proliferation and stimulates apoptosis in a variety of human tumor cell lines. In preclinical xenograft models, oral administration of XL518 results in sustained inhibition of pERK in tumor tissue, but not brain tissue, leading to tumor growth inhibition and regression at well tolerated doses.

Background

Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.

Indications

Cobimetinib is indicated in combination with vemurafenib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. As a single agent, cobimetinib is also indicated for the treatment of adult patients with histiocytic neoplasms.

Definition

ChEBI: Cobimetinib is a member of the class of N-acylazetidines obtained by selective formal condensation of the carboxy group of 3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid with the secondary amino group from the azetidine ring of 3-[(2S)-piperidin-2-yl]azetidin-3-ol. An inhibitor of mitogen-activated protein kinase that is used (as its fumarate salt) in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor and an antineoplastic agent. It is a member of piperidines, a N-acylazetidine, a tertiary alcohol, an aromatic amine, a secondary amino compound, a difluorobenzene and an organoiodine compound. It is a conjugate base of a cobimetinib(1+).

brand name

Cotellic

General Description

Class: dual threonine/tyrosine kinase; Treatment: melanoma with BRAF mutations; Other name: GDC-0973, XL518; Oral bioavailability = 46%; Elimination half-life = 44 h; Protein binding = 95%

Pharmacokinetics

Cobimetinib has only moderate oral bioavailability (46%), likely due to metabolism rather than incomplete absorption. However, it displays prolonged elimination half-life (44 h), which supports a once-daily dosing regimen (60 mg). Following oral administration, the unchanged cobimetinib and metabolite 4 were the major circulating components in the plasma up to 48 hours post dose (AUC0–48), accounting for 21% and 18% of all the circulating drug-related components, respectively (Fig. 4).
Figure 4. Major metabolic pathway of cobimetinib in  humans.

Pharmacokinetics

Cobimetinib is a reversible inhibitor of mitogen-activated protein kinase 1 (MAPK)/extracellular signal-regulated kinase 1 (MEK1) and MEK2. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a BRAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases. Cobimetinib is used in combination with vemurafenib because the clinical benefit of a BRAF inhibitor is limited by intrinsic and acquired resistance. Reactivation of the MAPK pathway is a major contributor to treatment failure in BRAF-mutant melanomas, approximately ~80% of melanoma tumors become BRAF-inhibitor resistant due to reactivation of MAPK signaling. BRAF-inhibitor-resistant tumor cells are sensitive to MEK inhibition, therefore cobimetinib and vemurafenib will result in dual inhibition of BRAF and its downstream target, MEK.

Clinical Use

Protein kinase inhibitor:
Treatment of unresectable or metastatic melanoma with a BRAF V600 mutation in combination with vemurafenib

Synthesis

Structurally, cobimetinib features an interesting azetidinol substructure appended to the 2-position of a piperidine, rendering the 2-carbon of the piperidine as a stereogenic center bearing the (S)-configuration. While the early discovery routes to cobimetinib relied on a piperidine resolution-based route for accessing the cobimetinib core, the scale route to this drug employs an impressive N-cyanomethyl oxazolidine chiral auxiliary-mediated sequence to induce strereocontrol, generating the requisite stereocenter with excellent selectivity and requiring no chromatographic purification in the overall synthetic sequence. Toward this end, the most likely scale synthetic approach was initiated with deprotonation of commercially available (3S,5R,8aS)-3-phenyl-hexahydrooxazolo[ 3,2-a]pyridine-carbonitrile (180), followed by addition of commercial 3-oxo-azetidine-1-carboxylic acid tert-butyl ester (181), yielded 182 in high purity (92%) after distillation and providing a rapid route to the core structure of cobimetinib. One-pot ring opening and reduction of 182 was accomplished by exposing this hemiaminal to acetic acid and sodium cyanoborohydride, giving rise to intermediate 183. This carbamate could be further reacted with aqueous HCl in toluene to liberate the azetidine amine salt in high purity (97.6%), which underwent immediate acylation with commercially available 2,3,4-trifluoro-benzoyl chloride (184) to enable formation of intermediate 185 in 85% purity after aqueous workup. Reductive cleavage of the chiral auxiliary of 185 with Pd/C and H2 under aqueous acidic conditions (AcOH, aq HCl) yielded the desired piperidine amine, which could be isolated as a solid (99.6% pure) after trituration with aqueous HCl. Finally, aromatic fluoride substitution with commercially available aniline 186 under basic conditions provided cobimetinib in 99.7% purity after slow precipitation from toluene (it is important to note that the authors offer no comment as to the regioselectivity of this aromatic substitution reaction). While the drug reportedly exists as a fumarate salt, no synthetic reports describing the conversion of cobimetinib to the corresponding fumarate salt were available in the chemical literature to our knowledge at the time of publication.

Synthesis_934660-93-2

Drug interactions

Potentially hazardous interactions with other drugs
Antifungals: concentration increased by itraconazole.
Antipsychotics: increased risk of agranulocytosis - avoid.

Metabolism

Metabolised by oxidation by CYP3A and glucuronidation by UGT2B7. Extensively metabolised and eliminated in faeces

Metabolism

Cobimetinib is mainly metabolized via CYP3A oxidation and UGT2B7 glucuronidation with no major metabolites formed.

Properties of XL518

Melting point: 165 - 166°C
Boiling point: 565.9±50.0 °C(Predicted)
Density  1.706
storage temp.  Refrigerator
solubility  Chloroform (Slightly), DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slig
form  Solid
pka 13.13±0.20(Predicted)
color  Off-White

Safety information for XL518

Computed Descriptors for XL518

Related products of tetrahydrofuran

You may like

  • 1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%
    1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%
    99903-60-3
    View Details
  • 88491-46-7 98%
    88491-46-7 98%
    88491-46-7
    View Details
  • 1823368-42-8 98%
    1823368-42-8 98%
    1823368-42-8
    View Details
  • 2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    1307449-08-6
    View Details
  • Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    25408-95-1
    View Details
  • 2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    1805639-70-6
    View Details
  • 1784294-80-9 98%
    1784294-80-9 98%
    1784294-80-9
    View Details
  • Lithium Clavulanate
    Lithium Clavulanate
    61177-44-4
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.